Zosuquidar (LY335979) 3HCl: Targeted P-glycoprotein Inhibition for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent and selective P-glycoprotein (P-gp) inhibitor that reverses multidrug resistance (MDR) in cancer models by directly blocking substrate efflux (Sun et al., 2025). It restores sensitivity to chemotherapeutics such as vinblastine and doxorubicin in vitro at low micromolar concentrations. The compound demonstrates efficacy in vivo, enhancing survival and antitumor activity without altering pharmacokinetics. Clinical trials confirm effective P-gp inhibition and minimal toxicity in combination regimens. APExBIO supplies Zosuquidar (LY335979) 3HCl (SKU A3956) for research applications, supporting robust and reproducible MDR reversal workflows [product page].

Biological Rationale

P-glycoprotein (P-gp; ABCB1) is an ATP-dependent efflux transporter expressed in tissues such as liver, brain, intestines, and tumors (Sun et al., 2025). It actively exports a broad range of substrates, including many chemotherapeutic agents, out of cells. In cancer, overexpression of P-gp is a hallmark of multidrug resistance (MDR), leading to reduced intracellular drug concentrations and poor treatment response [see Zosuquidar and the Future of MDR]. MDR is a major barrier in oncology, especially in acute myeloid leukemia (AML) and non-Hodgkin’s lymphoma. Inhibiting P-gp is a validated strategy to restore drug sensitivity and enhance chemotherapeutic efficacy.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a third-generation, highly selective P-gp inhibitor. It binds to the substrate-binding domain of P-gp, competitively inhibiting the efflux of chemotherapeutic drugs such as vinblastine, doxorubicin, etoposide, and paclitaxel. This results in increased intracellular drug accumulation and restored cytotoxicity in P-gp overexpressing cells. Zosuquidar does not significantly inhibit other ABC transporters, such as MRP1 or BCRP, at comparable concentrations [see Zosuquidar: P-gp Inhibitor for MDR Reversal]. Its high selectivity minimizes off-target effects and reduces the risk of undesired pharmacokinetic interactions.

Evidence & Benchmarks

• Zosuquidar at 0.5–1 μM restores sensitivity to vinblastine, doxorubicin, and paclitaxel in P-gp overexpressing leukemia cell lines, increasing cytotoxicity by >10-fold (Sun et al., 2025, DOI).
• In vivo, Zosuquidar enhances antitumor activity and prolongs survival in murine models of MDR leukemia and non-small cell lung carcinoma xenografts (Sun et al., 2025, DOI).
• Clinical phase I/II trials show effective P-gp inhibition and minimal toxicity when Zosuquidar is combined with CHOP in non-Hodgkin’s lymphoma and vinorelbine in advanced solid tumors (Sun et al., 2025, DOI).
• Pharmacokinetic studies confirm that Zosuquidar does not significantly alter the systemic exposure of co-administered chemotherapeutics (Sun et al., 2025).
• In vitro transporter assays (e.g., Caco-2, transfected HEK293) confirm high selectivity for P-gp over MRP1/BCRP at concentrations <2 μM (see Optimizing Chemotherapy Assays).

This article provides a granular, mechanism-focused update to prior summary articles such as Zosuquidar (LY335979) 3HCl and the Future of Multidrug Resistance, by offering structured, quantitative benchmarks and direct links to product integration workflows.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is primarily used in translational oncology research for reversing P-gp-mediated MDR. Typical applications include:

• Drug sensitization: Acute myeloid leukemia and solid tumor models with confirmed P-gp overexpression.
• Pharmacokinetic studies: Assessing transporter-mediated drug interactions without confounding metabolism by CYP450s.
• Clinical trial support: Evaluating combination regimens in early-phase studies for MDR reversal.

Common Pitfalls or Misconceptions

• Not effective against non-P-gp MDR: Zosuquidar does not inhibit other MDR transporters (MRP1, BCRP) at relevant concentrations.
• No impact on CYP450 metabolism: Zosuquidar is not a broad-spectrum metabolic inhibitor and does not alter CYP-mediated drug clearance.
• Not a cytotoxic agent: It does not kill cancer cells directly; efficacy depends on co-administered chemotherapeutics.
• Limited clinical data: While phase I/II data are promising, Zosuquidar is not yet approved as a standalone MDR reversal agent in clinical oncology.
• Storage instability in solution: Long-term storage of Zosuquidar solutions is not recommended due to stability loss; use fresh DMSO stocks stored at -20°C.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl is supplied by APExBIO as a powder, soluble in DMSO, and stable at -20°C. For in vitro assays, working concentrations of 0.5–2 μM are typical. Stock solutions should be freshly prepared and not stored long-term. In vivo studies use dosing regimens of 10–20 mg/kg by oral or intravenous routes in murine models [see Precision Reversal of MDR: Mechanistic Benchmarks]. Integration into workflow requires confirmation of P-gp expression in the target cell line or model and optimization of co-administered drug timing. For detailed protocols and troubleshooting, see the APExBIO product page for Zosuquidar (LY335979) 3HCl and related guides.

Compared to Optimizing P-gp Inhibition for MDR, this article provides a comprehensive, stepwise workflow for integrating Zosuquidar into both in vitro and in vivo assays with parameter documentation.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a validated, highly selective P-glycoprotein inhibitor that enables reversal of multidrug resistance in preclinical and early clinical models. Its integration into translational oncology workflows supports robust, reproducible research on MDR reversal, with a favorable safety and selectivity profile. Ongoing research will clarify its role in advanced clinical regimens and new cancer indications. For detailed specifications and ordering, see the APExBIO Zosuquidar (LY335979) 3HCl product page.